SHAFAQNA – An Iranian professor has received prestigious award Future Prize (Deutscher Zukunftspreis) jointly with a colleague in Bayer Pharma AG.
“This evening, the Federal President Joachim Gauck awarded the 2015, the Federal President’s award for innovation in science and technology, to the team and project “A relief for heart and lung – from nitroglycerin to innovative therapies,” wrote the official website of the award.
They discovered and developed treatment for two forms of pulmonary hypertension. Research on the innovative mechanism of action, Riociguat, is based on the findings of 130 years of treating angina pectoris with nitroglycerin. The innovative drug can considerably improve the critically-ill patient’s quality of life – for some, this drug from Germany is the first drug therapy ever available, the website report said.
The Federal President honors outstanding achievements in technology, engineering and natural science that have resulted in marketable, ready-for-use products. The prize was awarded this year for the 19th time and is endowed with € 250,000.
Further nominees for the Deutscher Zukunftspreis and accepted by the jury into the “circle of the best” were Ralf Bornefeld, Dr. Walter Hartner and Dr. Rudolf Lachner, Infineon Technologies AG, Munich and Regensburg, with the project “ Car radar technology – a lifesaver goes into series production” as well as Peter Sander, Prof. Claus Emmelmann, Frank Herzog, Airbus Operations GmbH, Hamburg, LZN Laser Zentrum Nord GmbH, Hamburg, Concept Laser GmbH, Lichtenfels, with their joint development on “3D printing in commercial aircraft engineering – A manufacturing revolution is taking off.”